The U.S. FDA has approved a molecularly targeted therapeutic to treat patients with advanced systemic mastocytosis. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic avapritinib (Ayvakit) to treat patients with...
They say age is just a number, but when it comes to cancer, getting older substantially increases your risk. Of the estimated 1.9 million cases of cancer diagnosed each year in the United States, approximately 80 percent are diagnosed in those over...
Triplet therapy shows promise for prostate cancer that was metastatic at diagnosis and more news of the week from the staff of Cancer Today magazine.
Most adults report inadequate knowledge of palliative care, according to a study published in the AACR journal Cancer Epidemiology, Biomarkers & Prevention.
A targeted therapy improves disease-free survival when given to people with certain hereditary mutations after breast cancer surgery, and more news of the week from Cancer Today.
The U.S. FDA has granted accelerated approval to the first KRAS inhibitor, along with two companion diagnostics, for certain patients with KRAS-mutated lung cancer. The U.S. Food and Drug Administration (FDA) granted accelerated approval...
A study finds that many people with solid tumors mount an antibody response following COVID-19 vaccination, and more news of the week from Cancer Today.
The FDA has granted accelerated approval to a molecularly targeted therapeutic along with a companion diagnostic to treat certain patients with cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
Melanoma is an aggressive form of skin cancer. While it is less common than skin cancers like basal cell carcinoma or squamous cell carcinoma, it is much more deadly due to its tendency to...
The U.S. Preventive Services Task Force lowers its recommended age to begin colorectal cancer screening to 45, and more news of the week from Cancer Today.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now